Melanie Sanford fought to get her son Hudson a breakthrough gene therapy to stop the progression of the fatal disease ...

Discover six innovative clinical-stage biotech companies fostering R&D in the Duchenne muscular dystrophy therapeutic space.

Givinostat, is an HDAC inhibitor (HDACi, a principle candidate, currently being developed for the treatment of DMD and BMD.

In a big homecoming night win, Hilliard Davidson's biggest play may have been a Jackson Maynard touchdown that didn't show up ...

Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular ...

This new genome-edited rat model of Becker muscular dystrophy (BMD) develops progressive heart failure with reduced ejection ...

A dispute over a Duchenne gene therapy highlights thorny issues surrounding FDA approvals and insurance policies.

A ‘Relive the 80s’ theme marked the occasion, which brought together 740 members of the commercial property industry at the ...

In the phase 2 FORWARD-53 study, the exon-skipping oligonucleotide WVE-N531 showed promising safety and efficacy in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.

Pratteln, Switzerland, September 24, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that Swissmedic, the Swiss Agency for Therapeutic Products, has accepted for review the marketing ...

Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for ...